Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-40.87%
0%
-40.87%
6 Months
-28.07%
0%
-28.07%
1 Year
13.68%
0%
13.68%
2 Years
-68.94%
0%
-68.94%
3 Years
-93.5%
0%
-93.5%
4 Years
-99.74%
0%
-99.74%
5 Years
-99.81%
0%
-99.81%
TME Pharma NV for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
0.59%
EBIT Growth (5y)
-3.57%
EBIT to Interest (avg)
-4.05
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.98
Sales to Capital Employed (avg)
0.02
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
6.33
EV to EBIT
-1.33
EV to EBITDA
-1.35
EV to Capital Employed
-4.46
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-354.52%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Mildly Bullish
Dow Theory
Bearish
Bearish
OBV
Mildly Bearish
Mildly Bearish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Annual Results Snapshot (Consolidated) - Dec'23
Dec'23
Dec'22
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-5.60
-11.90
52.94%
Interest
1.50
3.40
-55.88%
Exceptional Items
0.00
0.00
Consolidate Net Profit
-6.70
-15.10
55.63%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
Net Sales
YoY Growth in year ended Dec 2023 is 0.00% vs 0.00% in Dec 2022
Consolidated Net Profit
YoY Growth in year ended Dec 2023 is 55.63% vs -4.14% in Dec 2022
About TME Pharma NV 
TME Pharma NV
Pharmaceuticals & Biotechnology
NOXXON Pharma NV is a biotechnology company based in the Netherlands that focuses on cancer treatments. The Company's main product is the Spiegelmer platform. Spiegelmers are a variant of a drug class called aptamers, which are based on deoxyribonucleic acid (DNA) or ribonucleic acid (RNA) and are built on a backbone of mirror-image RNA or DNA - L-stereoisomers. The Company's lead candidate, NOX-A12, is under development as a combination therapy for a number of cancer indications using immuno-oncology approaches, such as immune checkpoint inhibition and current standards of care, such as chemotherapy and radiotherapy. The Company also develops NOX-E36, which is aimed at the treatment of complications arising from diabetic nephropathy.
Company Coordinates 
Company Details
Max-Dohrn-Str. 8-10 , BERLIN None : 10589
Registrar Details






